The objective of this study was to assess the influence of age on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Four hundred and sixty-nine patients were separated according to the age of onset of methotrexate treatment; before 65 yr (group 1, n = 416) and after 65 yr (group 2, n = 53). No difference was found in the evolution of clinical and biological parameters between the two groups. The number of patients in remission at the end of the study was equal. The frequency and type of side-effects were similar. No significant difference was found in the frequency and reasons for methotrexate withdrawal. We noted a trend towards lower therapeutic maintenance of methotrexate when prescribed after the age of 65 yr (P = 0.07, actuarial method). In conclusion, the age at initiation of methotrexate treatment probably did not influence its efficacy and toxicity in rheumatoid arthritis.
METHOTREXATE (MTX) is increasingly used in the treatment of various inflammatory conditions, the most common being rheumatoid arthritis (RA). MTX efficacy in RA patients has been demonstrated in open [1, 2] and double-blind randomized studies [3] [4] [5] [6] . However, RA frequently occurs in elderly persons whose renal function declines with age. Renal excretion constitutes the major route of elimination of MTX (~ 80% of the administered dose) [7] ; the altered drug phaimacokinetics in elderly subjects can increase the frequency of MTX side-effects in these patients.
We assessed this hypothesis by carrying out an open prospective study on 469 RA patients in our unit. In order to estimate a potential effect of age on the MTX efficacy and toxicity profile, patients were arbitrarily separated into two groups: < 65 and > 65 yr of age. This study suggests that the age of onset of MTX treatment does not influence its efficacy and toxicity in RA.
MATERIALS AND METHODS

Patients
All patients were recruited in our unit as in-and out-patients, and fulfilled the American College of Rheumatology (ACR) revised criteria for RA [8] . One hundred and ninety-one patients prospectively followed and previously reported [9] were included in this study. MTX use was decided by the physician usually in care of the patient after elimination of the usual contraindications. These were renal insufficiency (creatininaemia > 130 /imol/1), significant impairment of pulmonary and cardiac functions, previous or current history of hepatitis (alcoholic, viral or other causes), previous use of MTX with severe adverse events, haemoglobin (Hb) < 9 g/dl, white blood cells (WBQ <4000/mm\ platelet count (Plat) < 150 000/ mm 3 , aspartate transaminase (AST) and alanine transaminase (ALT) levels above twice the upper limit of normal.
A total of 469 RA patients treated with MTX between 1 January 1985 and 31 March 1994 were suitable for this study. The date on which the evaluation was performed was 1 November 1994. For 17 patients, we did not have any clear information on the tolerance to MTX: 15 in group 1 and two in group 2. For outcome analysis, we took the clinical [number of swollen joints (NSJ), number of painful joints (NPJ), morning stiffness (MS) and Ritchie's articular index (R)], biological and radiological data obtained at the last visit. For the number of swollen joints, 48 joints were assessed by recording the presence or absence of swelling on physical examination. For the number of painful joints, 24 joints (the temporomandibular, sternoclavicular, acromioclavicular were assessed as one joint; the metacarpophalangeal, proximal interphalangeal and metatarsophalangeal joints were assessed as one joint on each side) were assessed by recording the presence or absence of pain reported spontaneously by the patient. Remission was defined according to ACR criteria [10] . All clinical and biologically significant events which could be reasonably due to MTX were specifically and systematically recorded as side-effects. Haemoglobin levels, platelet counts, erythrocyte sedimentation rates (ESR) and C-reactive protein (CRP) were recorded.
The 469 RA patients treated with MTX were separated into two groups according to their age at onset of MTX treatment: before 65 yr, range 20-64 yr (n = 416, group 1) and after 65 yr (including 65), range 65-78 yr (n = 53, group 2). The characteristics of patients at baseline (onset of MTX treatment) are presented in Table I . The follow-up time was 36.1 ± 28 months (range 3-104) in group 1 and 28.2 ± 25.5 months (3-105) in group 2 (P = 0.04). The number of patients treated concomitantly with NSAIDs, t/vr = extra-articular features; DMARDs = number of previous disease-modifying anti-rheumatic drugs used; RF = rheumatoid factor positivity (>40IU/ml, nephelometry).
•Mann-Whitney C-test.
prednisone and the daily dose of prednisone at baseline were similar in the two groups (Table I) . Fifty-four patients received another DMARD during MTX treatment: 51 in group 1 (38 hydroxychloroquine, nine sulphasalazine, five thiol compounds and three gold salts; three patients receiving more than two DMARDs); three in group 2 (hydroxychloroquine).
There was no significant difference in the frequency of patients treated with two or more DMARDs between the two groups of patients, especially for patients treated with hydroxychloroquine. The number of patients treated concomitantly with folate was not markedly different (58/405 or 14.3% in group 1 vs 8/52 or 15.4% in group 2). The weekly folate intake was not different ( Table I) . The number of patients treated for 5 yr with MTX was the same in the two groups: 142/414 or 34.3% vs 16/53 or 30.2%. No differences were noted in the clinical and radiological data by the method of Larsen at baseline [11] . However, we noted a higher incidence of HLA DR4 in group 1 OP = 0.046). No difference was found for HLA DR1. Creatinine clearance was higher in group 1: 84.2 ± 26 (n = 315) vs 65.4 ± 21.3 ml/min in group 2 (n = 37) (P = 0.001). The MTX weekly and total doses were not different between the two groups of patients, unlike the MTX treatment time which was significantly longer in group 1 (P = 0.04) ( Table I ). The proportion of patients treated with MTX as first DMARD was not statistically different between the two groups (15/416 or 3.6% in group 1, and 1/53 or 1.9% in group 2).
HLA class II antigens were initially and principally determined by the serological method (n = 146), except when a few months ago the oligonucleotide method was routinely used [12, 13] . When available, the results of this latter method were systematically recorded (B = 40).
Statistical analysis
The results are presented as median ± standard deviation (s.D.). The analysis was conducted by comparing the variations in the different parameters between baseline and the end of the study in the two groups, and between the groups.
Comparisons between frequencies were made with the x 2 test with, when necessary, Yates' correction or Fisher's exact test. Comparisons between quantitative 
RESULTS
In the two groups, there was significant improvement in the clinical and biological parameters of RA activity between baseline and the end of the study (Table II) . The quality of the therapeutic response to MTX was not altered by initiating MTX after the age of 65. We did not find any significant difference between patients of group 1 (n = 416) and those of group 2 (n = 53), when comparing variations in the different clinical and biological parameters between baseline and the end of the study, i.e. data recorded on the patient's chart at the last visit (Table II) . The proportion of patients fulfilling ACR remission criteria [10] was similar in the two groups (8.9% vs 13.2%, respectively) ( Table II) . The weekly MTX dose was increased in the same range during follow-up in the two groups and the daily prednisone dosage reduced ( Table if) . The daily doses of prednisone at the end of the study were similar in the two groups: 9.7 ± 4.9 mg (n = 161) in group 1 vs 9.9 ± 4.5 mg (n = 24) in group 2. The number of patients treated with NSAIDs at the end of the study was similar in the two groups: 236/353 or 66.9% in group 1 vs 26/42 or 61.9% in group 2.
The frequencies of clinical and biological side-effects were not significantly different between the two groups (239/401 or 59.6% in group 1 vs 30/51 or 58.8% in group 2). No differences in the types of side-effects were observed between the two groups (Table III) . No difference was found in the evolution of the biological parameters of tolerance, although a trend towards a greater increase in the mean corpuscular volume (MCV) was noted in group 2 (Table IV) . We looked at predictive factors for the occurrence of side-effects in the group whose MTX treatment was initiated after the age of 65. The only significant difference was a greater incidence of extra-articular manifestations in patients who later developed a side-effect under treatment: 22/30 or 73.3% DS 8/21 or 38.1% (P = 0.02). Renal clearance at the onset of MTX treatment was not significantly different between patients with and without side-effects. Moreover, when patients were separated according to their quartile of creatinine clearance, we did not find any significant difference in the frequency of side-effects.
The distribution of reasons for MTX withdrawals when treatment was initiated after the age of 65 yr was not significantly different from that of patients treated before 65 yr (Table V) . The frequency of MTX withdrawals was significantly higher in group 2: 20/51 or 39.2% vs 94/401 or 23.4% in group 1 (P = 0.02). Eleven patients died (five in group 2 and six in group 1): three deaths were directly related to the rheumatoid process itself (amyloidosis with renal insufficiency, septic shock syndrome after bolus of methylprednisolone, shock after abrupt prednisone withdrawal). Two patients died of neoplasia (lung and gastric). Six patients died of cardiovascular disease. No deaths were related to MTX. When comparing the distribution of causes of MTX withdrawals, we found a statistically significant difference (P = 0.07) between the two groups, with a higher frequency of deaths in group 2 (5/20 or 25% vs 6/94 or 6.4%). As the deaths could not be attributed to MTX, the patients who died were excluded from the analysis. In such cases, no statistically significant difference in the frequency of •Pleuropericarditis (n « 1), cutaneous vasculitis (n = 3), nodulosis (" = 8).
tHepatitis C infection (n -2), psychological reasons (n •» 2), cancer (Hodglcin's disease, n = 1) and remission (n -3) .
MTX withdrawals was noted between the two groups (88/395 or 22.3% in group 1 vs 15/46 or 32.6% in group 2). Using the Lifetest procedure (actuarial method), we found a trend towards a lower probability of staying on MTX after the age of 65 (P = 0.07, Wilcoxon's test). The low number of patients for each reason of withdrawal did not allow us to look for predictive factors of the occurrence of these events.
DISCUSSION
The aim of this open prospective study on 469 RA patients treated with MTX was to determine whether the age of onset of MTX significantly influences the therapeutic efficacy and toxicity profile of this compound. The critical age was denned arbitrarily as 65 yr. We confirmed the clinical and biological efficacy of MTX in RA patients, as previously demonstrated in other studies [1] [2] [3] [4] [5] [6] . This result was obtained when MTX was prescribed before or after the age of 65 (Table II) . The number of induced remissions was the same in the two groups. The prednisone dosage was reduced in the same range in the two groups, and the number of patients treated concomitantly with NSAIDs did not vary significantly at baseline and at the end of the study.
Similar results were reported in three previous studies [14] [15] [16] . Wolfe and Cathey [14] studied 51 RA patients older than 65 yr (range 65-85) and compared their therapeutic response to that of 184 patients younger than 65 yr. Buchbinder et al. [15] showed that advanced age (3s 65 yr) did not predict lack of efficacy. Moreover, even though the threshold age of 65 yr was determined a priori, and is therefore debatable, the efficacy of MTX was not modified when the results were analysed by dividing the patients into four categories: <60, 60-64, 65-69 and >69yr [16] . No data are available yet on the radiographic effect of MTX after 65 yr of age.
In our study, the toxicity profile was similar in the two groups of patients. No differences were found in the frequencies and type of side-effects. No bias was detected as we noted a similar frequency of folate prescription in the two groups: 15.4% in group 1 and 14.3% in group 2. Furthermore, the weekly folate supplementation was identical (Table I ). The frequency of hydroxychloroquine prescription was the same in the two groups: 38/416 or 9.1% in group 1 vs 3/53 or 5.7% in group 2. Hydroxychloroquine was suggested in a retrospective analysis to lower transaminase levels in RA patients treated with MTX [17] . In spite of the absence of significant statistical differences, we noted a higher frequency of gastrointestinal side-effects in group 1 (Table III) . We have no explanation for this difference, as the MTX dosage was similar in the two groups. Haematological side-effects were more frequent, as could be expected, in group 2 (Table III) . The absence of a significant difference could have been due to a low statistical power of our study.
The results of published studies on the influence of age on the frequency of MTX side-effects in RA patients were similar to those reported here. Two studies did not find, as was also the case here, any increased incidence of side-effects with age [14, 16] . Wolfe and Cathey [14] only noted a higher, but non-significant, incidence of gastrointestinal symptoms in the oldest patients. In a recent study, the frequency of side-effects was not significantly different between patients divided into four categories: <60, 60-64, 65-69 and >69yr [16] .
When we looked for predictive factors of the occurrence of side-effects in group 2, we only noted a higher incidence of extra-articular features in patients who later developed a side-effect (P = 0.02). There was no observed difference concerning creatinine clearance at baseline. However, a higher statistically significant incidence of side-effects was recently found when creatinine clearance was <62.6ml/min, regardless of the age of the patients [16] . Kaye et al. [18] demonstrated that creatinine clearance was significantly lower in patients presenting with MTX side-effects as compared to patients without sideeffects. When we separated patients aged ^ 65 yr according to their quartiles of creatinine clearance, there was no significant difference in the frequency of side-effects. There is no satisfactory explanation for this discrepancy in the influence of creatinine clearance on the frequency of side-effects.
In this study, no increase in the frequency of MTX withdrawals was noted in group 2. Moreover, no difference was found in the reasons for these withdrawals. Deaths were excluded from the analysis as they were not related to MTX. The therapeutic maintenance rate (e.g. the number of patients who continued MTX treatment) tended to be lower in group 2 (P = 0.07). This could suggest, as no difference was found in the reasons for these withdrawals, that physicians caring for the patients prescribed MTX more cautiously to older patients. MTX could then have been stopped prematurely to avoid the occurrence of a serious side-effect. Two previous studies demonstrated that advanced age was a significant predictor of drug termination due to major toxicity [15, 19] . Age was not significantly different between patients experiencing a major adverse reaction and the controls [19] . The discrepancy between the results of these published studies and those of the present one could be due to the physician's decision to continue or stop MTX treatment. All of the studies were performed retrospectively and there was no pre-defined rule for making decisions on the discontinuation or not of MTX. Buchbinder et al. [15] showed a significant difference in the termination rates between rheumatologists. Moreover, as these studies were performed over a long period of time, physicians' decisions could have been modified as a result of training in the use of MTX.
Our study demonstrated that the efficacy and tolerance of MTX in RA patients aged > 65 yr over a period of nearly 8 yr was similar to that of younger patients. It should be borne in mind that this was an open study, so the efficacy data may be less valid and the two groups are not completely comparable. Indeed, the HLA DR4 frequency was greater in group 1. The HLA DR4 gene is one of the most relevant independent variables for indicating the outcome in RA [20] . This difference in DR4 frequency could explain the lower efficacy of MTX in group 1. In the present cohort, we did not note any difference in the frequency of serious side-effects or in their nature. These clinical and practical results are important since it was recently demonstrated that total body clearance and renal clearance of MTX are negatively correlated with the age of the patient [21] ; these authors recommended cautious use of MTX in elderly people. It should be stressed that the good tolerance noted in our study was obtained after careful selection of patients to be treated with MTX, while respecting strict exclusion criteria. Furthermore, MTX dosages in our study were relatively low, suggesting that higher dosages (up to 25 mg/week) could yield more toxic effects in group 2. The follow-up times (Table I) were marginally different (P = 0.04) between the two groups. It could be argued that longer treatment times in group 2 could be characterized by a higher incidence of side-effects or number of withdrawals. There should thus be regular and careful follow-up in the oldest patients. If these conditions are respected, MTX is of considerable interest for the treatment of severe RA in the elderly.
